Shares of Hims & Hers Health (HIMS) slipped 3% in premarket trading on Thursday after rival telehealth platform Ro introduced major price cuts to its weight-loss membership program, intensifying competition in the fast-growing GLP-1 subscription market
Lee Rosebush #PeptideMedicine #FDA #503A #Compounding Thank you, AAPM for all your effort leading up to, and during the hearing
[DOI] [PubMed] [Google Scholar] 159.Muraro P.A., Mariottini A., Greco R., Burman J., Iacobaeus E., Inglese M., Snowden J.A., Alexander T., Amato M.P., B L., et al
For most patients, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) require long-term use to maintain their benefits
Several theories have been proposed to support latter mainly focusing on calcium chelation